NCT05847348View on ClinicalTrials.gov

68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

PHASE3RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 19, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

July 30, 2026

Conditions
Biochemical Recurrence of Malignant Neoplasm of ProstateProstate CancerBCR Prostate Carcinoma
Interventions
DRUG

68Ga-PSMA-11

A single dose of 111 - 259 MBq administered intravenously over 3 -5 minutes

OTHER

PET/CT or PET/MRI

PET/CT or PET/MRI will be acquired no sooner than 50 minutes post injection and not later than 100 minutes post injection with 68Ga-PSMA-11

Trial Locations (8)

Unknown

RECRUITING

Peking University First Hospital, Beijing

RECRUITING

Xiangya Hospital Central South University, Changsha

RECRUITING

Nanfang Hospital Southern Medical University, Guangzhou

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

RECRUITING

West China Hospital of Sichuan University, Sichuan

RECRUITING

Wuhan Union Hospital, Wuhan

RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

RECRUITING

Affiliated Hosptial of Jiangnan University, Wuxi

All Listed Sponsors
collaborator

Grand Pharmaceutical (China) Co., Ltd.

OTHER

lead

Telix Pharmaceuticals (Innovations) Pty Limited

INDUSTRY